Quoin Pharmaceuticals Q4 2023 GAAP EPS $(2.08) Beats $(2.31) Estimate
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals reported a Q4 2023 GAAP EPS of $(2.08), surpassing the analyst consensus estimate of $(2.31) by 9.96%.
March 13, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quoin Pharmaceuticals reported a Q4 2023 GAAP EPS of $(2.08), exceeding the analyst consensus estimate of $(2.31) by 9.96%.
Beating the EPS estimate typically indicates better financial health and operational efficiency than expected, which can lead to positive investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100